Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Z. V. Revazova"'
Publikováno v:
Акушерство, гинекология и репродукция, Vol 15, Iss 1, Pp 80-92 (2021)
Aim: to summarize up-to-date world data on current opportunities of drug therapy in treatment of symptomatic myoma accompanied with heavy menstrual bleeding and anemia.Materials and Methods. A search of publications was carried out in the main intern
Externí odkaz:
https://doaj.org/article/ea4b9a8df9184d30b1c1950de1b84490
Publikováno v:
Медицинский совет, Vol 0, Iss 13, Pp 29-35 (2019)
Aim: To assess the efficacy and safety of ulipristal acetate (UA) use in uterine myoma patients before surgical treatment. Material and methods: 78 patients of reproductive age with uterine bleeding and anemia, who underwent laparoscopic myomectomy,
Externí odkaz:
https://doaj.org/article/2d3c444d953c4a0ba9c6b3adc4d50997
Publikováno v:
Медицинский совет, Vol 0, Iss 13, Pp 8-14 (2017)
Objective: assessment of the feasibility and safety of the use of ulipristal acetate on the basis of the clinical and morphological study.Materials and methods: the study involved 78 women with leiomyoma, abundant menstruation and anemia. Group I –
Externí odkaz:
https://doaj.org/article/4829d66ba4694fc5a519b8d47e03fca8
Autor:
A A Shiryaev, V.D. Melnikov, N. A. Sazonova, A. O. Vasilyev, A F Gabdullin, D Yu Pushkar, Yu.A. Kim, A. V. Zaitsev, Z V Revazova
Publikováno v:
Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny. 28
The first report of the new coronavirus infection (COVID-19) appeared at the end of December 2019 and in March,2020 the World Health Organization announced COVID-19 a pandemic. The steady number of newly detected cases increase predetermined the mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dce2fad280cdf0231908ef8f7b5b43
https://pubmed.ncbi.nlm.nih.gov/33219762
https://pubmed.ncbi.nlm.nih.gov/33219762
Publikováno v:
Arkhiv patologii. 79(3)
to investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493844b25e1bf8c1fa37742108e4ea20
https://pubmed.ncbi.nlm.nih.gov/28631712
https://pubmed.ncbi.nlm.nih.gov/28631712